Overview

A Study to Assess the Safety and Tolerability Profile of TR399 in Healthy Volunteers and Erectile Dysfunction Patients

Status:
Unknown status

Trial end date:
2018-03-31

Target enrollment:

Participant gender:

Summary

The purpose of this phase I/IIa study is to assess the safety and tolerability profile of TR399 in healthy volunteers and erectile dysfunction patients. This study will be conducted via a single-arm and open-label fashion.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Tritech Biopharmaceuticals Co., Ltd.

Collaborator:

A2 Healthcare Taiwan Corporation

Treatments:

Vardenafil Dihydrochloride